Loading news...
Shares of Evommune, Inc. (NYSE: EVMN - Get Free Report) have been assigned an average recommendation of "Buy" from the ten analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy
Last year, the biotechnology industry leaned heavily into the power of artificial intelligence (AI), using machine learning models to identify drug targets, to optimize molecules, and to make key predictions about trial outcomes. Alongside the continued proliferation of technology within the drug development space, companies with a focus on obesity, rare diseases, and oncology applications saw commercial achievements.
Evommune, Inc. (NYSE: EVMN - Get Free Report) Director Robert Lorne Hopfner acquired 1,000 shares of the stock in a transaction dated Friday, December 19th. The shares were bought at an average cost of $17.35 per share, for a total transaction of $17,350.00. Following the acquisition, the director owned 4,026 shares in the company, valued at
PALO ALTO, Calif.--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update. “The recent completion of our IPO puts us in a strong position to deliver on the years ahead, with three Phase 2 readouts across our two lead programs, EVO756 and EVO301, expe.
PALO ALTO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the pricing of its initial public offering of 9,375,000 shares of common stock at an initial public offering price of $16.00 per share.
PALO ALTO, Calif. , Oct. 30, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that on October 17, 2025, it filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") in connection with the commencement of a proposed initial public offering of its common stock.